Genmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Genmab A/S (NASDAQ:GMAB) posted its earnings results on Wednesday. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03), Zacks reports. The firm had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. During the same quarter last year, the firm posted $0.47 EPS. Genmab A/S updated its FY 2024 guidance to EPS.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $23.11 on Friday. The stock has a market cap of $15.29 billion, a price-to-earnings ratio of 19.10, a P/E/G ratio of 0.68 and a beta of 0.99. The company has a 50 day moving average of $24.57 and a 200-day moving average of $26.47. Genmab A/S has a one year low of $21.90 and a one year high of $32.89.

Analyst Ratings Changes

GMAB has been the subject of several research analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial reduced their target price on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Finally, Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.